High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer
- PMID: 8847139
- DOI: 10.1002/ijc.2910630611
High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer
Abstract
To evaluate the possible use of mutant ras as a biomarker for lung cancer, we have analyzed "normal appearing" lung tissue, lung tumor, lung metastases and sputum samples from patients with non-small cell lung cancer (NSCLC). As a control, we used lung tissue and sputum samples from patients without oncological diseases or lung disorders. Our analyses were performed with the aid of enriched PCR (EPCR), a method which enables detection of ras mutation even if present at low incidence. EPCR identified K-ras codon 12 mutations in 10% of lung tissues obtained from patients with no lung diseases, whereas the same mutation was detected in 60% of samples of normal appearing lung tissues obtained from patients with NSCLC, 62% of NSCLC tumors and 80% of metastases. Analysis of sputum samples of patients with NSCLC identified 47% to harbor mutant ras allele, whereas 12.5% of controls diagnosed with non-oncological lung diseases carried this mutation. Most of these mutations were detected with the aid of EPCR only, indicating that a minority of cells in a given sample harbor this mutation. The ability to detect K-ras codon 12 mutation in 60% of lung tissue samples and in 47% of sputum samples taken from patients with lung cancer (as compared with 10% and 12.5% of respective controls) points to the potential use of ras mutation as a biomarker for exposure and possible identification of patients who may be at higher risk of developing lung cancer.
Similar articles
-
K-ras mutation in sputum of patients with or without lung cancer.J Cell Biochem Suppl. 1996;25:172-6. J Cell Biochem Suppl. 1996. PMID: 9027615
-
Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis.Anal Biochem. 2004 Jan 1;324(1):92-9. doi: 10.1016/j.ab.2003.09.030. Anal Biochem. 2004. PMID: 14654050
-
Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.Eur J Med Res. 2000 Aug 18;5(8):341-6. Eur J Med Res. 2000. PMID: 10958767
-
Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT.J Clin Oncol. 1998 Sep;16(9):3061-8. doi: 10.1200/JCO.1998.16.9.3061. J Clin Oncol. 1998. PMID: 9738576
-
K-ras gene mutation in sputum samples containing atypical cells and adenocarcinoma cells in the lung.Carcinogenesis. 1996 Aug;17(8):1683-6. doi: 10.1093/carcin/17.8.1683. Carcinogenesis. 1996. PMID: 8761426
Cited by
-
Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening.Curr Oncol. 2022 Nov 15;29(11):8693-8719. doi: 10.3390/curroncol29110686. Curr Oncol. 2022. PMID: 36421339 Free PMC article. Review.
-
Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity.Cancers (Basel). 2021 Feb 13;13(4):778. doi: 10.3390/cancers13040778. Cancers (Basel). 2021. PMID: 33668583 Free PMC article. Review.
-
The Significance of Mitochondrial Dysfunction in Cancer.Int J Mol Sci. 2020 Aug 5;21(16):5598. doi: 10.3390/ijms21165598. Int J Mol Sci. 2020. PMID: 32764295 Free PMC article. Review.
-
Loss of Sirt2 increases and prolongs a caerulein-induced pancreatitis permissive phenotype and induces spontaneous oncogenic Kras mutations in mice.Sci Rep. 2018 Nov 7;8(1):16501. doi: 10.1038/s41598-018-34792-y. Sci Rep. 2018. PMID: 30405152 Free PMC article.
-
Aging and the rise of somatic cancer-associated mutations in normal tissues.PLoS Genet. 2018 Jan 4;14(1):e1007108. doi: 10.1371/journal.pgen.1007108. eCollection 2018 Jan. PLoS Genet. 2018. PMID: 29300727 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous